Company intelligence / Profile preview

Algernon Pharmaceuticals Inc.

Vancouver, British Columbia, Canadaalgernonpharmaceuticals.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company has completed a feasibility study and finalized its clinical trial design for a 40-patient Phase 2a DMT Stroke study. They recently sold their Ifenprodil research program for USD $2M cash and a 20% common share equity position in Seyltx, a U.S. based private drug development company, on March 27, 2024[9]. The company is now focusing on its intravenous formulation of AP-188 (DMT) for stroke research as its lead asset.

Therapeutic areas: OncologyPulmonologyNeurologyNephrology
Modalities: Small moleculesDMT (N,N-Dimethyltryptamine)
Industry: Biotech

Drug pipeline

1 asset

repirinast

Unknown

Partnerships

Seyltx Inc.

Beyond the preview

Go deeper on Algernon Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Algernon Pharmaceuticals Inc..

Explore the full profile